There really isn't anything new in the Citizen article. It's essentially the same brand of speculation as the Yost post. Murray has already contradicted the basic premise that his hands are tied and the estimated $50M internal salary cap is highly suspect.
This is also not new but since I don't think it's completely fruitless to investigate the matter I thought I'd share...
PurGenesis is not shuttered president insists
Incidently, Melnyk's personal wealth was estimated to be $973M in
this article by Macleans from this January concerning the same issue reported on in the Gazette. They tallied the federal and provincial loans to PurGenesis up to $8.2M not the $3M reported by the Gazette. (The Gazette seems to have a firmer foundation for their numbers, citing the numbers for each year and the source.)
It's pretty bleak news surrounding PurGenesis (their website has apparently gone from "under construction" to
"suspended" and their tax exemption expires in 2014 so they might wanna get moving).
The fact is though, Melnyk et al. aren't lying when they say that it is the nature of the pharmaceutical business to have a long, drawn out (read costly) development process.
Melnyk's other venture, Trimel, is similarly caught up in the process of FDA screening. They are currently heavily invested in the development of two drugs, CompleoTRT, a male-hormone enhancing drug, and Trefina, what's been called "the female viagra". Of the two only Compleo is relatively close to being available on the market having submitted their final application to the FDA. Trefina is still in stage II trials. That one though, could net a jackpot.
Combine this with PurGenesis's apparent stagnation (the Macleans article mentions one drug in stage II of FDA screening) and perhaps it's taking a bit longer than Melnyk expected to see some returns on his investments.